دورية أكاديمية

310P - Everolimus-exemestane (EE) vs palbociclib-letrozole (PL) or palbociclib-fulvestrant (PF) in the treatment of metastatic HR+, HER2- breast cancer. An indirect comparison with network meta-analysis

التفاصيل البيبلوغرافية
العنوان: 310P - Everolimus-exemestane (EE) vs palbociclib-letrozole (PL) or palbociclib-fulvestrant (PF) in the treatment of metastatic HR+, HER2- breast cancer. An indirect comparison with network meta-analysis
المؤلفون: Cherubini, C. 1, Gianni, L. 1, Stocchi, L. 1, Arcangeli, V. 1, Carminati, O. 1, Papi, M. 1, Pasini, G. 1, Fantini, M. 1, Nicoletti, S.V.L. 1, Tassinari, D. 1
المصدر: In Annals of Oncology September 2017 28 Supplement 5:v103-v103
قاعدة البيانات: ScienceDirect
الوصف
تدمد:09237534
DOI:10.1093/annonc/mdx365.073